[SCHEDULE 13G] Aptevo Therapeutics Inc SEC Filing
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B, and Waqas Khatri report beneficial ownership of 358,150 shares of Aptevo Therapeutics Inc. common stock (CUSIP 03835L405), representing 9.99% of the class. The reported shares are issuable on exercise of warrants held by the Reporting Persons and are subject to a 9.99% beneficial ownership blocker. The percentage calculation is based on 3,224,156 shares outstanding per the issuer's prospectus dated June 20, 2025, and the holdings are reported as of June 30, 2025. Each Reporting Person disclaims shared voting or dispositive power and reports sole voting and dispositive power over the 358,150 issuable shares. The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B e Waqas Khatri segnalano la propriet脿 effettiva di 358.150 azioni ordinarie di Aptevo Therapeutics Inc. (CUSIP 03835L405), pari al 9,99% della classe. Le azioni segnalate sono emettili mediante l'esercizio di warrant detenuti dalle persone che presentano la segnalazione e sono soggette a un blocco di propriet脿 effettiva del 9,99%. Il calcolo percentuale si basa su 3.224.156 azioni in circolazione secondo il prospetto dell'emittente datato 20 giugno 2025, e le partecipazioni sono riportate al 30 giugno 2025. Ciascuna parte che presenta la segnalazione nega di avere poteri condivisi di voto o dispositivi e dichiara di avere il pieno potere di voto e dispositivivo sulle 358.150 azioni emettibili. La documentazione include una certificazione che i titoli sono detenuti nell'ordinario corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B y Waqas Khatri informan la propiedad beneficiaria de 358.150 acciones ordinarias de Aptevo Therapeutics Inc. (CUSIP 03835L405), que representan el 9,99% de la clase. Las acciones informadas son susceptibles de emitirse mediante el ejercicio de warrants en poder de las Personas Informantes y est谩n sujetas a un bloqueo de titularidad beneficiaria del 9,99%. El c谩lculo porcentual se basa en 3.224.156 acciones en circulaci贸n seg煤n el prospecto del emisor fechado el 20 de junio de 2025, y las tenencias se informan al 30 de junio de 2025. Cada Persona Informante renuncia a cualquier poder compartido de voto o disposici贸n y declara tener el poder exclusivo de voto y disposici贸n sobre las 358.150 acciones emitibles. La presentaci贸n incluye una certificaci贸n de que los valores se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B 氚� Waqas Khatri電� Aptevo Therapeutics Inc. 氤错喌欤�(CUSIP 03835L405) 358,150欤�(齑濎＜鞚� 9.99%)鞚� 鞁れ唽鞙犽ゼ 氤搓碃頃╇媹雼�. 氤搓碃霅� 欤检嫕鞚� 氤搓碃鞚胳澊 氤挫湢頃� 鞗岆煱韸胳潣 頄夓偓搿� 氚滍枆 臧�電ロ暅 欤检嫕鞚措┌, 9.99%鞚� 靻岇湢 鞝滍暅(beneficial ownership blocker)鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟. 牍勳湪 瓿勳偘鞚� 氚滍枆鞚胳潣 2025雲� 6鞗� 20鞚检瀽 韴瀽靹る獏靹滌棎 霐半ジ 3,224,156欤� 氚滍枆欤检嫕鞚� 旮办鞙茧 頃橂┌, 氤挫湢 雮挫棴鞚� 2025雲� 6鞗� 30鞚� 旮办鞙茧 氤搓碃霅橃棃鞀惦媹雼�. 臧� 氤搓碃鞚胳潃 瓿惦彊鞚� 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潉 攵�鞚疙晿氅�, 氤搓碃霅� 358,150欤检棎 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖 靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠� 頄夓偓毳� 氇╈爜鞙茧 頃橃 鞎婌潓鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B et Waqas Khatri d茅clarent la propri茅t茅 b茅n茅ficiaire de 358鈥�150 actions ordinaires d'Aptevo Therapeutics Inc. (CUSIP 03835L405), repr茅sentant 9,99鈥�% de la cat茅gorie. Les actions d茅clar茅es sont susceptibles d'锚tre 茅mises lors de l'exercice de warrants d茅tenus par les personnes d茅clarante et sont soumises 脿 un verrouillage de propri茅t茅 b茅n茅ficiaire de 9,99鈥�%. Le calcul en pourcentage se base sur 3鈥�224鈥�156 actions en circulation selon le prospectus de l'茅metteur dat茅 du 20 juin 2025, et les participations sont d茅clar茅es au 30 juin 2025. Chaque personne d茅clarante d茅cline tout pouvoir de vote ou de disposition partag茅 et d茅clare d茅tenir le pouvoir exclusif de vote et de disposition sur les 358鈥�150 actions susceptibles d'锚tre 茅mises. Le d茅p么t comprend une certification que les titres sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B und Waqas Khatri melden wirtschaftliches Eigentum an 358.150 Stammaktien von Aptevo Therapeutics Inc. (CUSIP 03835L405), was 9,99% der Klasse entspricht. Die gemeldeten Aktien sind bei Aus眉bung von von den meldenden Personen gehaltenen Warrants aus眉bbar und unterliegen einer 9,99%-Beschr盲nkung der wirtschaftlichen Eigent眉merschaft. Die prozentuale Berechnung basiert auf 3.224.156 ausstehenden Aktien laut dem Prospekt des Emittenten vom 20. Juni 2025, und die Best盲nde werden zum 30. Juni 2025 gemeldet. Jede meldende Person weist gemeinsame Stimm- oder Verf眉gungsbefugnisse zur眉ck und gibt an, 眉ber die alleinigen Stimm- und Verf眉gungsrechte an den 358.150 aus眉bbaren Aktien zu verf眉gen. Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsgang gehalten werden und nicht zum Zweck einer 脛nderung oder Beeinflussung der Kontrolle.
- Significant disclosed stake: Reporting Persons identify a material economic position equal to 9.99% of the class, providing transparency to the market.
- Manager alignment: The filing clarifies the investment manager relationship (Ayrton Capital LLC manages the Fund), which helps stakeholders understand decision-making authority.
- Potential dilution: The holdings are shares issuable on warrants, which could dilute current common shareholders if exercised.
- Concentration risk: A near-10% position concentrates ownership and could influence trading or strategic dynamics despite the stated blocker.
Insights
TL;DR: A near-10% position via exercisable warrants signals a material stake but with a blocker limiting further accumulation.
The report documents a meaningful economic exposure: 358,150 shares equal to 9.99% of Aptevo's common stock on a stated base of 3,224,156 shares. These are warrant-based issuable shares, not necessarily currently outstanding common shares, which matters for timing and dilution analysis. The 9.99% ownership blocker prevents the Reporting Persons from exceeding the stated threshold without additional disclosure or structure changes, reducing the likelihood of immediate control-related actions. For investors, the filing is material as it reveals concentrated potential dilution and an aligned investment manager relationship between the Fund and Ayrton Capital LLC.
TL;DR: Disclosure is standard for a sizable derivative position; governance risk appears limited by the blocker and ordinary-course certification.
The Schedule 13G shows sole voting and dispositive power attributed to each Reporting Person for the 358,150 issuable shares, which is typical where a manager and affiliated fund act together. The explicit statement that holdings are held in the ordinary course and not to influence control, combined with the 9.99% blocker, suggests the Reporting Persons do not currently intend to pursue control changes. From a governance perspective, the position is material enough to warrant monitoring but does not itself indicate an imminent change in board or control dynamics.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B e Waqas Khatri segnalano la propriet脿 effettiva di 358.150 azioni ordinarie di Aptevo Therapeutics Inc. (CUSIP 03835L405), pari al 9,99% della classe. Le azioni segnalate sono emettili mediante l'esercizio di warrant detenuti dalle persone che presentano la segnalazione e sono soggette a un blocco di propriet脿 effettiva del 9,99%. Il calcolo percentuale si basa su 3.224.156 azioni in circolazione secondo il prospetto dell'emittente datato 20 giugno 2025, e le partecipazioni sono riportate al 30 giugno 2025. Ciascuna parte che presenta la segnalazione nega di avere poteri condivisi di voto o dispositivi e dichiara di avere il pieno potere di voto e dispositivivo sulle 358.150 azioni emettibili. La documentazione include una certificazione che i titoli sono detenuti nell'ordinario corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B y Waqas Khatri informan la propiedad beneficiaria de 358.150 acciones ordinarias de Aptevo Therapeutics Inc. (CUSIP 03835L405), que representan el 9,99% de la clase. Las acciones informadas son susceptibles de emitirse mediante el ejercicio de warrants en poder de las Personas Informantes y est谩n sujetas a un bloqueo de titularidad beneficiaria del 9,99%. El c谩lculo porcentual se basa en 3.224.156 acciones en circulaci贸n seg煤n el prospecto del emisor fechado el 20 de junio de 2025, y las tenencias se informan al 30 de junio de 2025. Cada Persona Informante renuncia a cualquier poder compartido de voto o disposici贸n y declara tener el poder exclusivo de voto y disposici贸n sobre las 358.150 acciones emitibles. La presentaci贸n incluye una certificaci贸n de que los valores se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B 氚� Waqas Khatri電� Aptevo Therapeutics Inc. 氤错喌欤�(CUSIP 03835L405) 358,150欤�(齑濎＜鞚� 9.99%)鞚� 鞁れ唽鞙犽ゼ 氤搓碃頃╇媹雼�. 氤搓碃霅� 欤检嫕鞚� 氤搓碃鞚胳澊 氤挫湢頃� 鞗岆煱韸胳潣 頄夓偓搿� 氚滍枆 臧�電ロ暅 欤检嫕鞚措┌, 9.99%鞚� 靻岇湢 鞝滍暅(beneficial ownership blocker)鞚� 鞝侅毄鞚� 氚涭姷雼堧嫟. 牍勳湪 瓿勳偘鞚� 氚滍枆鞚胳潣 2025雲� 6鞗� 20鞚检瀽 韴瀽靹る獏靹滌棎 霐半ジ 3,224,156欤� 氚滍枆欤检嫕鞚� 旮办鞙茧 頃橂┌, 氤挫湢 雮挫棴鞚� 2025雲� 6鞗� 30鞚� 旮办鞙茧 氤搓碃霅橃棃鞀惦媹雼�. 臧� 氤搓碃鞚胳潃 瓿惦彊鞚� 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潉 攵�鞚疙晿氅�, 氤搓碃霅� 358,150欤检棎 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 氤挫湢頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖 靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠� 頄夓偓毳� 氇╈爜鞙茧 頃橃 鞎婌潓鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B et Waqas Khatri d茅clarent la propri茅t茅 b茅n茅ficiaire de 358鈥�150 actions ordinaires d'Aptevo Therapeutics Inc. (CUSIP 03835L405), repr茅sentant 9,99鈥�% de la cat茅gorie. Les actions d茅clar茅es sont susceptibles d'锚tre 茅mises lors de l'exercice de warrants d茅tenus par les personnes d茅clarante et sont soumises 脿 un verrouillage de propri茅t茅 b茅n茅ficiaire de 9,99鈥�%. Le calcul en pourcentage se base sur 3鈥�224鈥�156 actions en circulation selon le prospectus de l'茅metteur dat茅 du 20 juin 2025, et les participations sont d茅clar茅es au 30 juin 2025. Chaque personne d茅clarante d茅cline tout pouvoir de vote ou de disposition partag茅 et d茅clare d茅tenir le pouvoir exclusif de vote et de disposition sur les 358鈥�150 actions susceptibles d'锚tre 茅mises. Le d茅p么t comprend une certification que les titres sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC 鈥� Segregated Master Portfolio B und Waqas Khatri melden wirtschaftliches Eigentum an 358.150 Stammaktien von Aptevo Therapeutics Inc. (CUSIP 03835L405), was 9,99% der Klasse entspricht. Die gemeldeten Aktien sind bei Aus眉bung von von den meldenden Personen gehaltenen Warrants aus眉bbar und unterliegen einer 9,99%-Beschr盲nkung der wirtschaftlichen Eigent眉merschaft. Die prozentuale Berechnung basiert auf 3.224.156 ausstehenden Aktien laut dem Prospekt des Emittenten vom 20. Juni 2025, und die Best盲nde werden zum 30. Juni 2025 gemeldet. Jede meldende Person weist gemeinsame Stimm- oder Verf眉gungsbefugnisse zur眉ck und gibt an, 眉ber die alleinigen Stimm- und Verf眉gungsrechte an den 358.150 aus眉bbaren Aktien zu verf眉gen. Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsgang gehalten werden und nicht zum Zweck einer 脛nderung oder Beeinflussung der Kontrolle.
FAQ
How many Aptevo (APVO) shares do the Reporting Persons beneficially own?
What percentage of APVO does 358,150 shares represent?
Are these currently outstanding common shares or exercisable warrants?
Do the Reporting Persons have voting and dispositive power over these shares?
Do the Reporting Persons intend to influence control of Aptevo (APVO)?
